Teprenone for steroid-related stomach injury in lupus
Treatments studied
Part of Digestive system clinical trials.
This study tests a medicine called Teprenone to see if it can protect the stomach from damage caused by high-dose steroids used to treat lupus. If you have SLE and take 30–60 mg of prednisone daily, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with systemic lupus erythematosus (SLE).
- You are taking a moderate to high dose of steroids (prednisone 30–60 mg daily).
- You do not have active stomach ulcers, bleeding, or stomach cancer.
- You have not had stomach surgery or certain endoscopic procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using mycophenolate mofetil plus tacrolimus can help people with lupus nephritis safely lower (taper) their prednisone to a low dose. It is designed for people whose kidney lupus has been well-controlled for at least 6 months.
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
This trial tests whether a lower starting dose of steroids can control kidney inflammation in children with lupus nephritis. It aims to reduce side effects while still treating the disease effectively.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This trial tests the safety of a new treatment called STR-P004 for people with systemic lupus erythematosus (SLE) or certain inflammatory muscle diseases that have not improved with standard therapies. It may be an option if your condition is hard to control.
This study compares two medications, GMPA and PPI, that protect the stomach during a stem cell transplant. It aims to see which one is better at preventing stomach problems and reducing the risk of a complication called graft-versus-host disease (aGVHD), where donor cells attack the patient's body.
Hear when a new Gastrointestinal and Digestive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.